$CRPOF News

Last published 2y ago

2y agoAEZS CRPOFAeterna Zentaris and Ceapro Complete Merger TransactionGlobeNewswireTORONTO and EDMONTON, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company") and Ceapro Inc. (TSXV:CZO) (OTCQX:CRPOF) ("Ceapro"), two innovative biopharmaceutical
2y agoCRPOFCeapro Inc. Reports 2023 Financial Results and Operational HighlightsGlobeNewswire– 2023 marked by Ceapro's achievement of key milestones and progress toward its next phase of growth – R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and the processing of
2y agoAEZS CRPOFCeapro Receives Final Court Approval for Merger with Aeterna ZentarisGlobeNewswireTORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna") and Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro") are pleased to announce that the
2y agoAEZS CRPOFAeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsGlobeNewswireTORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna") and Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro") are pleased to announce that securityholders of
2y agoAEZS CRPOFLeading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical CompanyGlobeNewswireISS states in its Aeterna Zentaris FOR recommendation that "on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear
2y agoCRPOFCeapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base BusinessGlobeNewswireEDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), today provided an update on its progress across its current business. On December 14, 2023, the
2y agoCRPOFCeapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna ZentarisGlobeNewswireEDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO) (OTCQX:CRPOF) ("Ceapro" or the "Company") is pleased to announce that it has mailed and filed a management information circular dated February
2y agoAEZS CRPOFAeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with CeaproGlobeNewswireAeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value propositionMore information and materials available at
2y agoAEZS CRPOFAeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical CompanyGlobeNewswireTORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna") and Ceapro Inc. (TSXV:CZO) (OTCQX:CRPOF) ("Ceapro"), two innovative biopharmaceutical development
2y agoCRPOFCeapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based DiseasesGlobeNewswire– Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute – No adverse reactions observed, and study can continue as planned EDMONTON, Alberta, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc.
2y agoCRPOFCeapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational HighlightsGlobeNewswire– Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market – Technology development focused on the PGX pilot scale units – Q3
3y agoCRPOFCeapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate UpdateGlobeNewswire- $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace reorganization
3y agoCRPOFCeapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, SymriseGlobeNewswire– Exclusive agreement extended from 3 to 5 years until December 31, 2026 – Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the cosmetic market –
3y agoCRPOFCeapro Announces Next Phase of Research Collaboration with the Angiogenesis FoundationGlobeNewswire– New studies to focus on speed of healing and molecular profiling of tissue regeneration induced by oat-derived bioactive products – EDMONTON, Alberta, July 18, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO,
3y agoCRPOFCeapro to Participate in the Virtual Investor Summer Spotlight SeriesGlobeNewswireEDMONTON, Alberta, July 05, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active
3y agoCRPOFCeapro Announces Results of 2023 Shareholders' MeetingGlobeNewswireEDMONTON, Alberta, June 07, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active
3y agoCRPOFCeapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue RegenerationGlobeNewswire– Data presented at 2023 Annual Meeting of the Wound Healing Society showed statistically significant results characterizing the in vivo bioactivity of Ceapro's oat-derived bioactive products on wound healing and tissue
3y agoCRPOFCeapro Inc. Appoints Michel Regnier as Senior Vice President, Technical OperationsGlobeNewswireEDMONTON, Alberta, April 27, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active
3y agoCRPOFCeapro Inc. Reports Record 2022 Financial Results and Operational HighlightsGlobeNewswire– 2022 marks Ceapro's best performance in Company history with record sales of $18,800,000 compared to $17,200,000 for 2021, representing a 10% increase year over year – Net profit after tax of $4,400,000 for the full
3y agoCRPOFCeapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International ConferenceGlobeNewswireEDMONTON, Alberta, March 23, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active
3y agoCRPOFCeapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American SocietyGlobeNewswire– Oral presentation to highlight unique results from pre-clinical studies characterizing the in vivo bioactivity of Ceapro's oat-derived bioactive products on angiogenesis, wound healing and tissue regeneration –
3y agoCRPOFCeapro to Present at the Virtual Investor 2023 Companies to Watch EventGlobeNewswireEDMONTON, Alberta, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active
3y agoCRPOFCeapro Announces Grant of Stock OptionsGlobeNewswireEDMONTON, Alberta, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active
4y agoCRPOFCeapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational HighlightsGlobeNewswire– R&D activities focused on the production of Avenanthramides pills for clinical trials and for scale-up of the PGX Technology – Q3 2022 sales of $3,845,000 vs $4,523,000 in Q3 2021; YTD sales increase 14% vs 2021 -
4y agoCRPOFCeapro Inc. Reports Record 2022 Second Quarter and Six-Month Financial Results and Provides Corporate UpdateGlobeNewswire– Company boasts highest second quarter sales to date; Q2 2022 sales of $5,500,000 vs $4,409,000 in Q2 2021, a 25% increase – YTD Sales increased 28% vs 2021 – $11,672,000 vs $9,110,000 – Income before tax of $2,177,000 in Q2 2022 vs $676
4y agoCRPOFCeapro Bolsters Executive Management Team with Appointment of Sigrun Watson as Chief Revenue OfficerGlobeNewswireRecognized commercial leader with over 20 years of experience across diverse healthcare industries Appointment marks strategic step in driving Company towards next phase of growth EDMONTON, Alberta, July 12, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (
4y agoCRPOFCeapro Announces Results of 2022 Shareholders' MeetingGlobeNewswireEDMONTON, Alberta, June 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmeti
4y agoCRPOFCeapro Inc. Announces Appointment of Geneviève Foster to Board of DirectorsGlobeNewswireEDMONTON, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmet
4y agoCRPOFCeapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational HighlightsGlobeNewswire– FY 2021 record sales of $17,200,000 compared to $15,100,000 for FY 2020, representing a 14% increase year over year; Ceapro's best sales performance in Company history – Net profit of $2,842,000 for the full year of 2021 compared to a net profit
4y agoCRPOFCeapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, SymriseGlobeNewswire- Symrise to distribute and commercialize Ceapro's high value active ingredients in the cosmetic market - - Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the cosmetic market -
4y agoCRPOFCeapro Bolsters Board of Directors with Appointment of Top Executive from Global Pharmaceutical IndustryGlobeNewswireEDMONTON, Alberta, March 02, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmet
4y agoCRPOFCeapro Inc. to Present at the Virtual Investor 2022 Top Picks ConferenceGlobeNewswireEDMONTON, Alberta, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmet
4y agoAEZS AIM AREC CNSP+9JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27thACCESS Newswire- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a f
4y agoCRPOFCeapro Inc. Announces R&D Funding to Support PGX Technology ProjectGlobeNewswire– PGX Technology further recognized as a disruptive technology – Additional support paves the way for the manufacturing of pharmaceutical-grade yeast beta glucan (YBG) EDMONTON, Alberta, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZ
4y agoCRPOFCeapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol LevelsGlobeNewswireEDMONTON, Alberta, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmet
5y agoCRPOFCeapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta Glucan Processed with Pressurized Gas eXpanded Technology (PGX-YBG)GlobeNewswireMcMaster's research team discovers new mechanism of action for PGX-YBG PGX-YBG demonstrates ability to reprogram macrophages on its own PGX-YBG may be a suitable therapeutic solution for patients with fibrotic lung disease and late stage COVID-19 p
5y agoCRPOFCeapro Inc. to Present at the Virtual Investor Roundtable EventGlobeNewswireEDMONTON, Alberta, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmet
5y agoAREC CNSP CRPOF CYTH+6JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18thACCESS Newswire- Access the event and schedule of presenting companies at virtualinvestorco.com -- Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies - PITTSTOWN, NJ / ACCESSWIRE / November 4, 2021 /
5y agoCRPOFCeapro Inc. to Present at H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireEDMONTON, Alberta, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosme
5y agoCRPOFCeapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational HighlightsGlobeNewswire– Company continues to increase R&D activities to advance clinical and preclinical programs – – Second quarter sales of $4,409,000 compared to $4,666,000 for second quarter 2020 – – Cash generated from operations of $2,128,000 in Q2 2021
5y agoCRPOFCeapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan and AvenanthramidesGlobeNewswire– Research focused on addressing root cause of disease and tissue damage for diseases such as COVID-19 – – Leveraging the unique expertise and methods developed by the Angiogenesis Foundation to conduct pre-clinical studies to characterize the
5y agoCRPOFCeapro Inc. Expands Collaboration with Montreal Heart Institute (MHI) with New Clinical Study Evaluating Flagship Product, AvenanthramideGlobeNewswire- Second human trial to be conducted as part of a long-term Master Service Agreement with MHI- Phase 1 study with Ceapro's pharmaceutical grade avenanthramide to be coordinated by MHI's Montreal Health Innovations Coordinating Center (MHICC) and led by D
5y agoCRPOFCeapro Announces Results of 2021 Shareholders' MeetingGlobeNewswireEDMONTON, Alberta, June 01, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV:CZO, OTCQX:CRPOF) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmeti
5y agoCRPOFCeapro Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Operational HighlightsGlobeNewswireMaintained production operations during COVID-19 pandemic, providing customers with essential products and completing integration of manufacturing site, while ensuring the health and safety of employees Substantially increased sales, net profits and ca
5y agoCRPOFCeapro Inc. Announces Successful Completion of Collaborative Research and Development Program with University of AlbertaGlobeNewswire– Project significantly advances broadening the application and utility of Ceapro’s proprietary, first-in-class technologies to develop innovative delivery systems composed of new chemical complexes –...